A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques.
A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques.
复制标题
DOI：
10.1126/scitranslmed.abo6160
复制
发表时间：
2022-10-05
影响因子：
17.1
通讯作者：
中科院分区：
文献类型：
--
作者：
靶向严重急性呼吸道综合征冠状病毒2型（SARS-CoV-2）刺突糖蛋白的人单克隆抗体（mAb）为预防和治疗2019冠状病毒病（COVID-19）提供了一种有前途的方法。鉴于全球疫苗接种率不理想，接种疫苗的个体免疫力下降，以及出现令人担忧的SARS-CoV-2变异体，mAb用于COVID-19预防的使用可能会增加，并且在某些情况下可能需要与疫苗一起使用。然而，目前尚不清楚单克隆抗体的施用是否会影响SARS-CoV-2疫苗的免疫原性。使用腺病毒载体为基础的SARS-CoV-2疫苗，我们表明，同时给予疫苗与SARS-CoV-2单克隆抗体不会减少疫苗诱导的体液或细胞免疫在食蟹猴。这些结果表明，SARS-CoV-2单克隆抗体和基于病毒载体的SARS-CoV-2疫苗可以一起施用，而不会损失任一产品的效力。需要进行额外的研究来评价mAb与其他疫苗平台的联合给药。人SARS-CoV-2单克隆抗体混合物可以与基于SARS-CoV-2病毒载体的疫苗共同施用。
Human monoclonal antibodies (mAbs) that target the spike glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) offer a promising approach for the prevention and treatment of coronavirus disease 2019 (COVID-19). Given suboptimal global vaccination rates, waning immunity in vaccinated individuals, and the emergence of SARS-CoV-2 variants of concern, the use of mAbs for COVID-19 prevention may increase and may need to be administered together with vaccines in certain settings. However, it is unknown whether administration of mAbs will impact the immunogenicity of SARS-CoV-2 vaccines. Using an adenovirus vector-based SARS-CoV-2 vaccine, we show that simultaneous administration of the vaccine with SARS-CoV-2 mAbs does not diminish vaccine-induced humoral or cellular immunity in cynomolgus macaques. These results suggest that SARS-CoV-2 mAbs and viral vector-based SARS-CoV-2 vaccines can be administered together without loss of potency of either product. Additional studies will be required to evaluate co-administration of mAbs with other vaccine platforms. A human SARS-CoV-2 monoclonal antibody cocktail can be co-administered with a SARS-CoV-2 viral vector-based vaccine.
登录
查看更多内容
两种抗体鸡尾酒中和中和的遗传和结构基础。
影响因子：
28.3
作者：
Dong J;Zost SJ;Greaney AJ;Starr TN;Dingens AS;Chen EC;Chen RE;Case JB;Sutton RE;Gilchuk P;Rodriguez J;Armstrong E;Gainza C;Nargi RS;Binshtein E;Xie X;Zhang X;Shi PY;Logue J;Weston S;McGrath ME;Frieman MB;Brady T;Tuffy KM;Bright H;Loo YM;McTamney PM;Esser MT;Carnahan RH;Diamond MS;Bloom JD;Crowe JE Jr
通讯作者：
Crowe JE Jr
影响因子：
64.8
作者：
Zost SJ;Gilchuk P;Case JB;Binshtein E;Chen RE;Nkolola JP;Schäfer A;Reidy JX;Trivette A;Nargi RS;Sutton RE;Suryadevara N;Martinez DR;Williamson LE;Chen EC;Jones T;Day S;Myers L;Hassan AO;Kafai NM;Winkler ES;Fox JM;Shrihari S;Mueller BK;Meiler J;Chandrashekar A;Mercado NB;Steinhardt JJ;Ren K;Loo YM;Kallewaard NL;McCune BT;Keeler SP;Holtzman MJ;Barouch DH;Gralinski LE;Baric RS;Thackray LB;Diamond MS;Carnahan RH;Crowe JE Jr
通讯作者：
Crowe JE Jr
影响因子：
17.1
作者：
Loo YM;McTamney PM;Arends RH;Abram ME;Aksyuk AA;Diallo S;Flores DJ;Kelly EJ;Ren K;Roque R;Rosenthal K;Streicher K;Tuffy KM;Bond NJ;Cornwell O;Bouquet J;Cheng LI;Dunyak J;Huang Y;Rosenbaum AI;Pilla Reddy V;Andersen H;Carnahan RH;Crowe JE Jr;Kuehne AI;Herbert AS;Dye JM;Bright H;Kallewaard NL;Pangalos MN;Esser MT
通讯作者：
Esser MT
影响因子：
9.2
作者：
Bos R;Rutten L;van der Lubbe JEM;Bakkers MJG;Hardenberg G;Wegmann F;Zuijdgeest D;de Wilde AH;Koornneef A;Verwilligen A;van Manen D;Kwaks T;Vogels R;Dalebout TJ;Myeni SK;Kikkert M;Snijder EJ;Li Z;Barouch DH;Vellinga J;Langedijk JPM;Zahn RC;Custers J;Schuitemaker H
通讯作者：
Schuitemaker H
影响因子：
82.9
作者：
VanBlargan LA;Errico JM;Halfmann PJ;Zost SJ;Crowe JE Jr;Purcell LA;Kawaoka Y;Corti D;Fremont DH;Diamond MS
通讯作者：
Diamond MS